Abstract:BackgroundIn the current study, we sought to characterise the methylation haplotypes and nucleosome positioning patterns of placental DNA and plasma cell-free DNA of pregnant women with early-onset preeclampsia using whole genome bisulphite sequencing (WGBS) and methylation capture bisulphite sequencing (MCBS) and further develop and examine the diagnostic performance of a generalised linear model (GLM) by incorporating the epigenetic features for early-onset preeclampsia.MethodsThis case-control study recruited pregnant women aged at least 18 years who delivered their babies at our Hospital. In addition, non-pregnant women with no previous history of diseases were included. Placental samples of the villous parenchyma were taken at the time of delivery and venous blood was drawn from pregnant women during non-invasive prenatal testing at 12-15 weeks of pregnancy and nonpregnant women during the physical check-up. WGBS and MCBS were carried out of extracted genomic DNA. Then, we established the GLM by incorporating preeclampsia-specific methylation haplotypes and nucleosome positioning patterns and examined the diagnostic performance of the model by receiver operating characteristic (ROC) curve analysis.ResultsThe study included 135 pregnant women and 50 non-pregnant women. Our high-depth MCBS revealed notably different DNA methylation and nucleosome positioning patterns between women with and without preeclampsia. Preeclampsia-specific hypermethylated sites were found predominantly in the promoter regions and particularly enriched in CTCF on the X chromosome. Totally, 2379 preeclampsia-specific methylation haplotypes were found across the entire genome. ROC analysis showed that the area under the ROC curve (AUC) was 0.938 (95%CI 0.877, 1.000). At a GLM cut-off of 0.341, the AUC was the maximum, with a sensitivity of 95.6% and a specificity of 89.7%.ConclusionPregnant women with early-onset preeclampsia exhibit DNA methylation and nucleosome positioning patterns in placental and plasma DNA. Early-onset preeclampsia is a potentially dangerous condition that can have a profound impact on the health of both the expectant mother and her unborn child. This condition is particularly concerning because it's challenging to predict who may be affected using conventional methods such as monitoring blood pressure. In our research, we've developed an innovative, non-invasive approach to predict the onset of early preeclampsia. We do this by analysing the genetic material of the developing baby, which can be found in the mother's blood. Our method has shown remarkable accuracy in our testing populations, and its implications are substantial. By providing an early warning system, this breakthrough can benefit pregnant women immensely. It means that early-onset preeclampsia can be identified and addressed well before it becomes a serious health threat. This allows for timely medical interventions and treatments, significantly improving the well-being of both mothers and their precious little ones.

High-resolution epigenomic liquid biopsy for noninvasive phenotyping in pregnancy

A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing.

Microarray-Based Method to Analyze DNA Methylation of Maternal Plasma in Pregnant Women

Effective Noninvasive Zygosity Determination By Maternal Plasma Target Region Sequencing

Noninvasive inferring expressed genes and in vivo monitoring of the physiology and pathology of pregnancy using cell-free DNA

Cell-free DNA Methylation and Transcriptomic Signature Prediction of Pregnancies with Adverse Outcomes

Microarray Based DNA Methylation Assay in Maternal Plasma of Pregnant Women

DNA Methylome Profiling of Maternal Peripheral Blood and Placentas Reveal Potential Fetal DNA Markers for Non-Invasive Prenatal Testing.

The signature of cancer methylation markers in maternal plasma: Factors influencing the development and application of cancer liquid biopsy assay

Epigenetic phenotype of plasma cell-free DNA in the prediction of early-onset preeclampsia

Genome-wide methylation profiling of cell-free DNA in maternal plasma using Methylated DNA Sequencing (MeD-seq)

Non-invasive determination of gene expression in placental tissue using maternal plasma cell-free DNA fragmentation characters

Quantification of Fetal DNA by Using Methylation-Based Discrimination

Distinct DNA Methylation Signatures in Maternal Blood Reveal Unique Immune Cell Shifts in Preeclampsia and the Pregnancy-Postpartum Transition

Integrity of Cell-Free DNA in Maternal Plasma Extracellular Vesicles As a Potential Biomarker for Non-Invasive Prenatal Testing

Detection of fetal trisomy and single gene disease by massively parallel sequencing of extracellular vesicle DNA in maternal plasma: a proof-of-concept validation

Genome-wide association study of maternal plasma metabolites during pregnancy

Feasibility Study of Using Fetal DNA in Maternal Plasma for Non‐invasive Prenatal Diagnosis

Comprehensive Evaluation of the Impact of Whole-Genome Bisulfite Sequencing (WGBS) on the Fragmentomic Characteristics of Plasma Cell-Free DNA

Quantification And Application Of The Placental Epigenetic Signature Of The Rassf1a Gene In Maternal Plasma

The Fragmentation Patterns of Maternal Plasma Cell-Free DNA and Its Applications in Non-Invasive Prenatal Testing.